Terms: = Lung cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Clinical Outcome
15 results:
1. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Sakai K; Tsuboi M; Kenmotsu H; Yamanaka T; Takahashi T; Goto K; Daga H; Ohira T; Ueno T; Aoki T; Nakagawa K; Yamazaki K; Hosomi Y; Kawaguchi K; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Okabe K; Yamamoto N; Nishio K
Cancer Sci; 2021 Jan; 112(1):388-396. PubMed ID: 33185928
[TBL] [Abstract] [Full Text] [Related]
2. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y; Sun Y; Zhao W; Ma Y; Yan Z; Nie X
Biomed Pharmacother; 2020 May; 125():109958. PubMed ID: 32036219
[TBL] [Abstract] [Full Text] [Related]
3. muc1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract] [Full Text] [Related]
4. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract] [Full Text] [Related]
5. [Childhood pleuropulmonary blastoma: a clinicopathologic study of 16 cases].
Zhang N; Fu L; Zhou C; Wang L; Lang Z; He L
Zhonghua Bing Li Xue Za Zhi; 2014 Nov; 43(11):747-52. PubMed ID: 25582253
[TBL] [Abstract] [Full Text] [Related]
6. muc1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.
Khodarev NN; Pitroda SP; Beckett MA; MacDermed DM; Huang L; Kufe DW; Weichselbaum RR
Cancer Res; 2009 Apr; 69(7):2833-7. PubMed ID: 19318547
[TBL] [Abstract] [Full Text] [Related]
7. Usefulness of monitoring the circulating Krebs von den lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of FHIT, CTNNB1, and muc1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract] [Full Text] [Related]
9. Primary invasive micropapillary carcinoma of the colon.
Sakamoto K; Watanabe M; De La Cruz C; Honda H; Ise H; Mitsui K; Namiki K; Mikami Y; Moriya T; Sasano H
Histopathology; 2005 Nov; 47(5):479-84. PubMed ID: 16241995
[TBL] [Abstract] [Full Text] [Related]
10. [Nodular bronchioloalveolar carcinoma at early stage].
Mazieres J; Daste G; Giron J; Marson V; Berjaud J; Dahan M; Bachaud JM; Carles P; Didier A
Rev Mal Respir; 2003 Feb; 20(1 Pt 1):61-7. PubMed ID: 12709635
[TBL] [Abstract] [Full Text] [Related]
11. [A clinicopathological study of clear cell sarcoma of the kidney].
He L; Fu L; Wang L; Li P; Lang Z
Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):422-5. PubMed ID: 11866983
[TBL] [Abstract] [Full Text] [Related]
12. Enhancement of metastatic properties of pancreatic cancer cells by muc1 gene encoding an anti-adhesion molecule.
Satoh S; Hinoda Y; Hayashi T; Burdick MD; Imai K; Hollingsworth MA
Int J Cancer; 2000 Nov; 88(4):507-18. PubMed ID: 11058865
[TBL] [Abstract] [Full Text] [Related]
13. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer.
Koukourakis MI; Giatromanolaki A; Guddo F; Kaklamanis L; Vignola M; Kakolyris S; Turley H; Georgoulias V; Bonsignore G; Gatter KC; Harris AL
J Immunother; 2000 Jan; 23(1):104-14. PubMed ID: 10687143
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor.
Keime-Guibert F; Graus F; Broët P; Reñé R; Molinuevo JL; Ascaso C; Delattre JY
Neurology; 1999 Nov; 53(8):1719-23. PubMed ID: 10563618
[TBL] [Abstract] [Full Text] [Related]
15. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies.
Graus F; Vega F; Delattre JY; Bonaventura I; Reñé R; Arbaiza D; Tolosa E
Neurology; 1992 Mar; 42(3 Pt 1):536-40. PubMed ID: 1312683
[TBL] [Abstract] [Full Text] [Related]
